Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran

Zhou, Wei; Wang, Tao; Zhu, Lingjuan; Wen, Minghua; Hu, Lihua; Huang, Xiao; You, Chunjiao; Li, Juxiang; Wu, Qinghua; Bao, Huihui; Cheng, Xiaoshu

doi:10.1097/cm9.0000000000000423

Cited by 4 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From February 2015 to December 2017, 929 participants were recruited from 12 hospitals throughout China. Details regarding the research population definition, inclusion, and exclusion criteria were discussed in detail in a previously published article ( 10 ).…”

Section: Methodsmentioning

confidence: 99%

Diastolic blood pressure achieved at target systolic blood pressure (120-140 mmHg) and dabigatran-related bleeding in patients with nonvalvular atrial fibrillation: a real-world study

Zhou

et al. 2020

Anatol J Cardiol

View full text Add to dashboard Cite

Objective: Elevated systolic blood pressure (SBP) can significantly increase the bleeding risk in patients with atrial fibrillation (AF). However, it is unclear whether elevated diastolic blood pressure (DBP), in the presence of well-controlled SBP is also associated with bleeding. Therefore, we aimed to examine the specific relationship between DBP and bleeding in patients with AF treated with anticoagulants and had well-controlled SBP. Methods: We analyzed data from 542 of 929 patients with nonvalvular AF (NVAF) treated with dabigatran from the Monitor System for the Safety of Dabigatran Treatment study (MISSION-AF) who had a SBP of 120–140 mm Hg at the time of enrollment. The association between DBP and bleeding was analyzed using multivariate logistic regression and smooth curve fitting (penalized spline method). Threshold saturation effect analysis was used to show the nonlinear relationship between DBP and bleeding. Results: After 3 months of follow-up, 49 bleeding events occurred. Compared with participants with DBP <80 mm Hg, those with DBP ≥80 mm Hg had a 118% higher bleeding risk [hazard ratio (HR): 2.18; 95% confidence interval (CI): 1.19, 3.98; p<0.05]. The smooth curve showed a nonlinear relationship between DBP and bleeding risk, and the inflection point of DBP was 80 mm Hg. When DBP was ≥80 mm Hg, the bleeding risk increased by 59% (HR: 1.59; 95% CI: 1.16, 2.19; p<0.05) for every 5 mm Hg increase in DBP. Conclusion: Upon achieving an optimal SBP (120–140 mm Hg), a higher DBP might be associated with a higher bleeding risk in patients with NVAF treated with dabigatran.

show abstract

Section: Methodsmentioning

confidence: 99%

Diastolic blood pressure achieved at target systolic blood pressure (120-140 mmHg) and dabigatran-related bleeding in patients with nonvalvular atrial fibrillation: a real-world study

Zhou

et al. 2020

Anatol J Cardiol

View full text Add to dashboard Cite

show abstract

Developing a machine learning model for bleeding prediction in patients with cancer-associated thrombosis receiving anticoagulation therapy

Grdinic,

Radovanovic,

Gleditsch

et al. 2024

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis

Chen¹,

Zhong²,

Tu³

et al. 2020

WJCC

View full text Add to dashboard Cite

BACKGROUND The incidence and prevalence of atrial fibrillation are increasing each year, and this condition is one of the most common clinical arrhythmias. AIM To investigate the levels and significance of serum fibroblast growth factor 23 (FGF-23) and miR-208b in patients with atrial fibrillation and their relationship with prognosis. METHODS From May 2018 to October 2019, 240 patients with atrial fibrillation were selected as an observation group, including 134 with paroxysmal atrial fibrillation and 106 with persistent atrial fibrillation; 150 patients with healthy sinus rhythm were selected as a control group. The serum levels of FGF-23 and miR-208b in the two groups were measured. In the observation group, cardiac parameters were determined by echocardiography. RESULTS The serum levels of FGF-23 and miR-208b in the observation group were 210.20 ± 89.60 ng/mL and 5.30 ± 1.22 ng/mL, which were significantly higher than the corresponding values in the control group ( P < 0.05). In the observation group, the serum levels of FGF-23 and miR-208b in patients with persistent atrial fibrillation were 234.22 ± 70.05 ng/mL and 5.83 ± 1.00 ng/mL, which were significantly higher than the corresponding values in patients with paroxysmal atrial fibrillation ( P < 0.05). The left atrial dimension (LAD) of patients with persistent atrial fibrillation was 38.81 ± 5.11 mm, which was significantly higher than that of patients with paroxysmal atrial fibrillation ( P > 0.05). The serum levels of FGF-23 and miR-208b were positively correlated with the LAD ( r = 0.411 and 0.382, P < 0.05). In the observation group, the serum levels of FGF-23 and miR-208b in patients with a major cardiovascular event (MACE) were 243.30 ± 72.29 ng/mL and 6.12 ± 1.12 ng/mL, which were significantly higher than the corresponding values in patients without a MACE ( P < 0.05). CONCLUSION The serum levels of FGF-23 and miR-208b are increased in patients with atrial fibrillation and are related to the type of disease, cardiac parameters, and prognosis.

show abstract

Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran

Cited by 4 publications

References 35 publications

Diastolic blood pressure achieved at target systolic blood pressure (120-140 mmHg) and dabigatran-related bleeding in patients with nonvalvular atrial fibrillation: a real-world study

Diastolic blood pressure achieved at target systolic blood pressure (120-140 mmHg) and dabigatran-related bleeding in patients with nonvalvular atrial fibrillation: a real-world study

Developing a machine learning model for bleeding prediction in patients with cancer-associated thrombosis receiving anticoagulation therapy

Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis

Contact Info

Product

Resources

About